- Home
- JVA vs CYTH Comparison
JVA vs CYTH Comparison
Compare JVA & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVA
- CYTH
- Stock Information
- Founded
- JVA 1971
- CYTH 1990
- Country
- JVA United States
- CYTH United States
- Employees
- JVA N/A
- CYTH N/A
- Industry
- JVA Packaged Foods
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- JVA Consumer Staples
- CYTH Health Care
- Exchange
- JVA Nasdaq
- CYTH Nasdaq
- Market Cap
- JVA 32.2M
- CYTH 31.9M
- IPO Year
- JVA 2005
- CYTH N/A
- Fundamental
- Price
- JVA $5.82
- CYTH $0.91
- Analyst Decision
- JVA
- CYTH Buy
- Analyst Count
- JVA 0
- CYTH 3
- Target Price
- JVA N/A
- CYTH $0.95
- AVG Volume (30 Days)
- JVA 288.6K
- CYTH 4.5M
- Earning Date
- JVA 03-17-2025
- CYTH 03-17-2025
- Dividend Yield
- JVA N/A
- CYTH N/A
- EPS Growth
- JVA N/A
- CYTH N/A
- EPS
- JVA 0.39
- CYTH N/A
- Revenue
- JVA $78,562,298.00
- CYTH $870,725.00
- Revenue This Year
- JVA N/A
- CYTH N/A
- Revenue Next Year
- JVA N/A
- CYTH $24.49
- P/E Ratio
- JVA $15.91
- CYTH N/A
- Revenue Growth
- JVA 15.24
- CYTH N/A
- 52 Week Low
- JVA $1.15
- CYTH $0.55
- 52 Week High
- JVA $6.53
- CYTH $1.79
- Technical
- Relative Strength Index (RSI)
- JVA 64.18
- CYTH 53.59
- Support Level
- JVA $5.61
- CYTH $0.85
- Resistance Level
- JVA $6.53
- CYTH $1.45
- Average True Range (ATR)
- JVA 0.67
- CYTH 0.13
- MACD
- JVA 0.10
- CYTH -0.00
- Stochastic Oscillator
- JVA 73.31
- CYTH 22.83
About JVA Coffee Holding Co. Inc.
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.